top of page
iStock-1204272696.webp

EASING THE BURDEN OF CHEMOTHERAPY-INDUCED DIARRHEA (CID) IN DOGS

WHAT IS CHEMOTHERAPY-INDUCED DIARRHEA (CID)?

Large dog breeds, Small dog breeds, CID, Chemotherapy treatments in dogs

CID is a common side effect of approved chemotherapy treatments in dogs.

Digestive complications like CID occur because of how chemotherapy drugs are designed to work

Digestive complications like CID occur because of how chemotherapy drugs are designed to work.

Chemotherapy drugs can attack the cells in the lining of the stomach and digestive tract since they cannot distinguish between some normal cells, dog stomach lining, dog digestive tract

Chemotherapy drugs can attack the cells in the lining of the stomach and digestive tract, since they cannot distinguish between some normal cells.

®

SIGN UP FOR ALL THE LATEST NEWS ON Canalevia  -CA1

iStock-1196727492.webp

WHAT ARE THE BURDENS OF CID IN DOGS?

Rounded_Rec-13.png
Rounded_Rec-13.png
Rounded_Rec-13.png

Costly

For dogs with CID, approximately 42% of those patients require a future veterinary visit, 29% require rehydration, and 9% require hospitalization. 2

Disruptive

More than half of veterinarians reported that CID interferes with their patient’s chemotherapy treatment plan. 1

Dehydration

Severe or prolonged diarrhea can result in significant dehydration and metabolic disturbances due to fluid loss.

HOW DOES Canalevia-CA1 HELP MY DOG?

FINAL_MOA_Consumer-41.png

Chloride

Sodium

Chloride channels

Gut lining

Fluid

Canalevia-CA1

Normal

Diarrhea

Canalevia-CA1

Gut lining, Chloride channels, Water secretion, Sodium, Chloride
Diarrhea, Gut lining, Chloride channels, Chloride, Sodium, Water, Canalevia-CA1 modifies the Chloride ion channels to normalize water flow in the GI tract
Gut lining, Chloride channels, Chloride, Sodium, Water, Canalevia-CA1 acts locally and is not absorbed into the blood stream, ensuring a well tolerated and non-toxic treatment
iStock-1162639219.webp
Rounded_Rec-13.png

Chloride channels provide pathways for fluid secretion in the intestine.

Rounded_Rec-13.png

Canalevia-CA1 acts within the GI tract targeting chloride channels on the lining of the intestine.

Rounded_Rec-13.png

Canalevia-CA1 modifies the chloride ion channels to normalize fluid flow in the GI tract.

Rounded_Rec-13.png

Canalevia-CA1 acts locally and is not absorbed into the blood stream, ensuring a well tolerated and non-opioid treatment.

TREATING DIARRHEA IN YOUR DOG UNDERGOING CHEMOTHERAPY

Dog Owners, Veterinarians, Canalevia-CA1, Older dogs, Small dog breeds, Large dog breeds, Caring for your dog, Treating Diarrhea in your dog undergoing chemotherapy, Dog owner's guide

1 & 2 SOURCE: Jaguar-sponsored survey of US veterinarians

Contact Us

 

1 (877) 787-3001

info@canalevia.com

  • Instagram
  • Facebook
  • LinkedIn

Location

 

Jaguar Animal Health

200 Pine Street, Suite 600

San Francisco, CA 94104

Canalevia_byJAG_Logo_White.png

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.

IMPORTANT SAFETY INFORMATION

For oral use in dogs only. Not for use in humans. Keep Canalevia®-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

bottom of page